Clinical predictors of chemotherapy-induced nausea and vomiting in breast cancer patients receiving adjuvant doxorubicin and cyclophosphamide

Annals of Pharmacotherapy

Volumn 43, Issue 3, 2009, Pages 444-452

  Shih, Vivianne ^a   Wan, Hee Siew ^a   Chan, Alexandre ^a,b  

^a DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Breast cancer; Chemotherapy; Nausea; Vomiting

Indexed keywords

APREPITANT; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; GRANISETRON; METOCLOPRAMIDE; ONDANSETRON;

ADULT; AGED; ARTICLE; BREAST CANCER; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROGNOSIS; PROPHYLAXIS; RISK FACTOR; SCORING SYSTEM; VOMITING;

ADULT; AGE FACTORS; AGED; ANTIEMETICS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; HUMANS; MEDICATION ADHERENCE; MIDDLE AGED; NAUSEA; PROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; VOMITING;

EID: 62949089933     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1L437     Document Type: Article

References (35)

1. Early Breast Cancer Trialists' Collaborative Group. Polychemotherapy for early breast cancer: an overview of the randomized trials. Lancet 1998;352:930-42.
2. Roila F, Hesketh PJ, Herrstedt J, et al. Prevention of chemotherapy- and radiotherapy-induced emesis: results of the Perugia International Antiemetic Consensus Conference. Ann Oncol 2006;17:20-8.
3. Griffin AM, Butow PN, Coates AS, et al. On the receiving end. V: patient perceptions of the side effects of cancer chemotherapy in 1993. Ann Oncol 1996;7:189-95.
4. Coates AS, Abraham S, Kaye SB, et al. On the receiving end: patient perception of the side effects of chemotherapy. Eur J Cancer Clin Oncol 1983;19:203-8.
5. Roscoe JA, Morrow GR, Hickok JT. et al. Nausea and vomiting remain a significant clinical problem: trends over time in controlling chemotherapy induced nausea and vomiting in 1413 patients treated in community clinical practices. J Pain Sympt Manage 2000;20:113-21.
6. De Boer-Dennert M. de Wit R, Schmitz PI, et al. Patient perceptions of the side-effects of chemotherapy: the influence of 5-HT3 antagonists. Br J Cancer 1997;76:1055-61.
7. Kris MG, Hesketh PJ, Somerfield MR, et al. American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol 2006;24:2932-47.
8. Levitt M. Warr D, Yelle L, et al. Ondansetron compared with dexamethasone and metoclopramide as antiemetics in the chemotherapy of breast cancer with cyclophosphamide, methotrexate, and fluorouracil. N Engl J Med 1993;328:1081-4.
9. Stewart A, McQuade B, Cronje JD. et al. Ondansetron compared with granisetron in the prophylaxis of cyclophosphamide-induced emesis in out-patients: a multicentre, double-blind, double-dummy, randomised, parallel-group study. Oncology 1995;52:202-10.
10. Clavel M, Bonneterre J, d'Allens H, et al. Oral ondansetron in the prevention of chemotherapy-induced emesis in breast cancer patients. Eur J Cancer 1995;31:15-9.
11. Warr DG, Hesketh PJ, Gralla RJ, et al. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol 2005;23:2822-30.
12. Atkins L, Fallowfield L. Intentional and non-intentional non-adherence to medication amongst breast cancer patients. Eur J Cancer 2006;42: 2271-6.
13. Palimeri FM, Barton DL. Challenges of oral medications in patients with advanced breast cancer. Semin Oncol Nurs 2007;23(suppl):S17-22.
14. Clark PM, Karagoz T, Apikoglu-Rabus S, et al. Effect of pharmacist-led patient education on adherence to tuberculosis treatment. Am J Health Syst Pharm 2007;64:497-505.
15. Booth CM, demons M, Dranitsaris G, et al. Chemotherapy-induced nausea and vomiting in breast cancer patients: a prospective observational study. J Support Oncol 2007;5:374-80.
16. Lai S, Wong ZW, Sandanaraj E, et al. Influence of ABCB1 and ABCG2 polymorphisms on doxorubicin disposition in Asian breast cancer patients. Cancer Sci 2008;99:816-23.
17. Bloechl-Daum B, Deuson RR, Mavros P, et al. Delayed nausea and vomiting continue to reduce patient's quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment. J Clin Oncol 2006;24:4472-8.
18. Cohen L, de Moor CA, Eisenberg P, et al. Chemotherapy-induced nausea and vomiting: incidence and impact on patient quality of life at community oncology settings. Support Care Cancer 2007;15:497-503.
19. Ballatori E, Riola F. Ruggeri B, et al. The impact of chemotherapy-induced nausea and vomiting on health-related quality of life. Support Care Cancer 2007;15:179-85.
20. Dibble SL, Israel J, Nussey B, et al. Delayed chemotherapy-induced nausea in women treated for breast cancer. Oncol Nurs Forum 2003;30:40-7.
21. Liau CT, Chu Nei-Min, Liu Hsueh-Erh, et al. Incidence of chemotherapy-induced nausea and vomiting in Taiwan: physicians' and nurses' estimation versus patients' reported outcomes. Support Care Cancer 2005; 13:277-86.
22. Foubert J, Vaessen G. Nausea: the neglected symptom? Eur J Oncol Nurs 2005;9:21-32.
23. Love RR, Leventhal H, Easterling DV, et al. Side effects and emotional distress during cancer chemotherapy. Cancer 1989;63:604-12.
24. Lehane E, McCarthy G. Intentional and unintentional medication non- adherence: a comprehensive framework for clinical research and practice? A discussion paper. Int J Nurs Stud 2007;44:1468-77.
25. Pritchard MT, Butow PN, Stevens MM, et al. Understanding medication adherence in pediatric acute lymphoblastic leukemia: a review. J Pediatr Hematol Oncol 2006;28:816-23.
26. Hartley MC, McKinley BP, Rogers EA, et al. Differential expression of prognostic factors and effect on survival in young (≤s40) breast cancer patients: a case-control study. Am Surg 2006;72:1189-94; discussion 1194-5.
27. 3 receptor antagonists in the treatment of acute chemotherapy induced nausea and vomiting. Cancer Invest 2000; 18:163-73.
28. Ritter HL Jr. Gralla RJ, Hall SW, et al. Efficacy of intravenous granisetron to control nausea and vomiting during multiple cycles of cisplatin- based chemotherapy. Cancer Invest 1998;16:87-93.
29. Tebbi CK. Treatment compliance in childhood and adolescence. Cancer 1993;71:3441-9.
30. Chan A, Shih V, Chew L. Evolving roles of oncology pharmacists in Singapore: a survey on prescribing patterns of antiemetics for chemotherapy induced nausea and vomiting (CINV) at a cancer centre. J Oncol Pharm Pract 2008;14:23-9.
31. Hermansen CJ, Wiederholt JB. Pharmacist-patient relationship development in an ambulatory clinic setting. Health Commun 2001;13:307-25.
32. De Young M. Research on the effects of pharmacist-patient communication in institutions and ambulatory care sites, 1969-1994. Am J Health Syst Pharm 1996;53:1277-91.
33. Molassiotis A. Yam BMC, Yung H, et al. Pretreatment factors predicting the development of postchemotherapy nausea and vomiting in Chinese breast cancer patients. Support Care Cancer 2002;10:139-45.
34. Carey MP, Burish TG. Etiology and treatment of the psychological side effects associated with cancer chemotherapy, a critical review and discussion. Psychol Bull 1988;104:307-25.
35. Wyshak G, Barsky AJ. Relationship between patient self-ratings and physician ratings of general health, depression, and anxiety. Arch Fam Med 1994;3:419-24.